Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?

Patients with type 2 diabetes (T2D) are at an increased risk of cardiovascular disease (CVD). Cardiovascular risk in these patients should be considered as a continuum, and comprehensive treatment strategies should aim to target multiple disease risk factors. Large‐scale clinical trials of sodium‐gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Giorgino, Francesco, Vora, Jiten, Fenici, Peter, Solini, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496739/
https://www.ncbi.nlm.nih.gov/pubmed/32285611
http://dx.doi.org/10.1111/dom.14055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496739/
https://www.ncbi.nlm.nih.gov/pubmed/32285611
http://dx.doi.org/10.1111/dom.14055

Ejemplares similares